INmune Bio 2023 Year-End Financial Performance Analysis
Thursday, 28 March 2024, 20:06
INmune Bio 2023 Year-End Results:
Financial Performance Overview:
- GAAP EPS: -$1.67 (misses estimates by $0.02)
- Revenue: $0.15M (beats estimates by $0.01M)
The 2023 year-end financial results of INmune Bio signify a mixture of positive and negative factors. While the revenue exceeded expectations, the GAAP EPS fell short, indicating a complex financial scenario for the company.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.